Florida Cancer Specialists & Research Institute

Nathan Walcker, CEO at Florida Cancer Specialists & Research Institute (FCS), highlights some of the recent partnerships and initiatives at FCS to improve community-based oncology care from a value-based perspective.

Kiana Mehring, MBA, director of strategic partnerships, managed care at Florida Cancer Specialists & Research Institute (FCS), discusses her role working in managed care and some of the new strategic partnership initiatives at FCS.

Lucio Gordan, MD, president and managing physician, Florida Cancer Specialists & Research Institute (FCS), discusses how FCS has learned to adapt during difficult times, including COVID-19, Hurricane Ian, and current drug shortages.

Gustavo Fonseca, MD, FACP, physician director of clinical research, Florida Cancer Specialists & Research Institute (FCS), discusses the results from a late phase complexity analysis on barriers to clinical trials regarding biopsy requirements.

Jennifer Gass, PhD, FACMG, associate director, Genetics Laboratory, Florida Cancer Specialists & Research Institute, discusses the recent Genetics Laboratory, which focuses on next-generation sequencing (NGS) testing in oncology care.

Judy Wang, MD, medical oncologist and clinical trials investigator at Sarah Cannon Research Institute at Florida Cancer Specialists & Research Institute, discussed the mechanism of action and rationale for studying CLN-619, an anti-MICA/B antibody, with and without pembrolizumab in patients with solid tumors.

Blasini joined FCS in 2012 as a hematopathologist and has served as co-director of the pathology laboratory since 2018.

Florida Cancer Specialists recently released a case study that outlined its role in the evolution of a first-line therapy for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) that recently received FDA approval.

News from our Strategic Alliance Partners.

Being able to treat patients with non–small cell lung cancer (NSCLC) and a KRAS mutation with sotorasib has been exciting, and now there’s another drug available with the approval of adagrasib at the end of 2022, explained Lucio Gordan, MD, of Florida Cancer Specialists & Research Institute.

In abstracts presented at the 64th American Society of Hematology Annual Meeting and Exposition, the investigational BTK inhibitor pirtobrutinib showed promising efficacy and safety in several types of B-cell lymphoma.

BRAF mutations were addressed in depth this year, having been mentioned in 3 of this year’s top 5 articles. Also discussed were a first-in-its-class combination treatment approval and potential indicators of increased skin cancer risk.

The quest to deliver better cancer care—with better outcomes and patient experience—is not a one-size-fits-all journey, as seen in panels during the Community Oncology Alliance (COA) Payer Exchange Summit, held in Tyson’s Corner, Virginia.

Making value-based payment models work in cancer care requires close attention to the financial and quality measures and a commitment to culture change, said experts gathered October 25 at the Community Oncology Alliance Payer Exchange Summit.

Panelists who have reviewed the Enhancing Oncology Model (EOM) say it puts additional requirements on practices with reduced monthly payments, and its risk modeling could put a small practice out of business.

NCODA and Florida Cancer Specialists & Research Institute jointly announced the development of a novel oncology stakeholder education exchange program.

Florida Cancer Specialists & Research Institute announced the formation of additional precision oncology capabilities and resources comprised of geneticists, informatics specialists, and database technologies that will enhance patient care through comprehensive analysis of molecular data.

Florida Cancer Specialists & Research Institute (FCS) recently adopted a new mission, vision, and values that will serve as the foundation for their operations.

In the second of 2 parts, Nathan H. Walcker, MBA, CEO of Florida Cancer Specialists & Research Institute (FCS), discusses what he’d like value-based care to look like going forward. CMS ended the Oncology Care Model (OCM) yesterday after 6 years and has invited practices to apply for a successor model, the Enhancing Oncology Model.

In the first of 2 parts, Nathan H. Walcker, MBA, CEO of Florida Cancer Specialists & Research Institute (FCS), discusses the future of value-based care for the practice as the Oncology Care Model comes to an end today. This week, CMS announced it will launch a successor model.

Nathan H. Walcker, MBA, CEO of Florida Cancer Specialists & Research Institute (FCS) since August 2020, discusses the future of value-based care for the practice as the Oncology Care Model comes to an end.

Florida Cancer Specialists & Research Institute (FCS) announced a partnership with Strayer University’s Grads to Work program that will help prepare a diverse population of students for job opportunities and support them while they continue their education.